Table 5.
CD4+ CCR5+ | CD4+ CCR3+ | |||
---|---|---|---|---|
− | + | − | + | |
CD95 expression | ||||
Acute (A) | 1·3 ± 0·3 | 16·7 ± 1·5* | 1·5 ± 0·4 | 3·2 ± 0·5* |
Healed (H) | 1·8 ± 0·5 | 4·1 ± 1·9 | 1·2 ± 0·2 | 2·0 ± 0·3 |
CD95L expression | ||||
Acute (A) | 3·6 ± 0·5* | 5·2 ± 0·8* | 1·0 ± 0·4 | 11·2 ± 1·1* |
Healed (H) | 1·9 ± 0·3 | 0·8 ± 0·2 | 1·1 ± 0·8 | 2·5 ± 1·1 |
Frozen PBMC from five VL patients, studied in acute and healed phases of disease, were cultured for 24 hr in medium alone (–) and in the presence of LAg (+) (2 × 107 equivalent promastigotes). Cells were treated with anti-CD4+ monoclonal antibody IS3-conjugated, anti-CD95 PE-conjugated or biotin–streptavidin PE-conjugated anti-human CD95L, and anti-CCR3 or anti-CCR5 FITC-conjugated antibodies. Data are expressed as mean percentage ± SE.
P < 0·05: significantly different from healed subjects. Percentage of CD95 expression in five healthy controls (CTR): CD4+ CCR5+ (1·2 ± 0·3); CD4+ CCR3+ (0·2 ± 0·01). Percentage of CD95L expression in CTR: CD4+ CCR5+ (0·3 ± 0·03); CD4+ CCR3+ (0·5 ± 0·01).